Pedro E Cahn

Summary

Country: Argentina

Publications

  1. doi request reprint Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Lancet 382:700-8. 2013
  2. pmc Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial
    Darrell H S Tan
    University Health Network, 585 University Ave, 13N 1323, Toronto, Ontario, M5G 2N2 Canada
    Trials 11:113. 2010
  3. pmc Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters
    M Eugenia Socías
    Hospital J A Fernandez, Cerviño 3356, Buenos Aires, Argentina
    J Int AIDS Soc 14:40. 2011
  4. pmc Asking the right questions: developing evidence-based strategies for treating HIV in women and children
    Quarraisha Abdool Karim
    Department of Epidemiology, Columbia University, New York, USA
    BMC Public Health 11:388. 2011
  5. doi request reprint Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    AIDS 25:929-39. 2011
  6. doi request reprint Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine
    Pedro Cahn
    Fundacion Huesped, Angel Peluffo 3932, Buenos Aires C1202ABB, Argentina
    J Antimicrob Chemother 65:213-7. 2010
  7. ncbi request reprint Tuberculosis and HIV: a partnership against the most vulnerable
    Pedro Cahn
    Fundacion Huesped, Angel Peluffo 3932 C1202ABB, Buenos Aires, Argentina
    J Int Assoc Physicians AIDS Care (Chic) 2:106-23. 2003
  8. ncbi request reprint Raltegravir: a new antiretroviral class for salvage therapy
    Pedro Cahn
    Department of Clinical Research, Fundacion Huesped, Buenos Aires, Argentina C1202ABB
    Lancet 369:1235-6. 2007
  9. pmc Beyond the first 25 years: The International AIDS Society and its role in the global response to AIDS
    Pedro Cahn
    International AIDS Society, 33, Chemin de l Avanchet, Geneva, Switzerland
    Retrovirology 3:85. 2006
  10. ncbi request reprint Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Clin Infect Dis 43:1347-56. 2006

Collaborators

Detail Information

Publications30

  1. doi request reprint Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Lancet 382:700-8. 2013
    ..We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance...
  2. pmc Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial
    Darrell H S Tan
    University Health Network, 585 University Ave, 13N 1323, Toronto, Ontario, M5G 2N2 Canada
    Trials 11:113. 2010
    ..Suppression of herpes simplex virus type 2 (HSV-2) may be a novel strategy for achieving this goal because HSV-2 is associated with clinically significant increases in HIV viral load, the primary driver of HIV disease progression...
  3. pmc Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters
    M Eugenia Socías
    Hospital J A Fernandez, Cerviño 3356, Buenos Aires, Argentina
    J Int AIDS Soc 14:40. 2011
    ..Diagnosis of primary HIV infection (PHI) has important clinical and public health implications. HAART initiation at this stage remains controversial...
  4. pmc Asking the right questions: developing evidence-based strategies for treating HIV in women and children
    Quarraisha Abdool Karim
    Department of Epidemiology, Columbia University, New York, USA
    BMC Public Health 11:388. 2011
    ..The guideline's new goals present an opportunity for advancing the women and children's agenda outlined in the Consensus Statement...
  5. doi request reprint Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    AIDS 25:929-39. 2011
    ..twice-daily darunavir/ritonavir (DRV/r) in treatment-experienced patients with no DRV resistance-associated mutations (RAMs) at screening...
  6. doi request reprint Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine
    Pedro Cahn
    Fundacion Huesped, Angel Peluffo 3932, Buenos Aires C1202ABB, Argentina
    J Antimicrob Chemother 65:213-7. 2010
    ....
  7. ncbi request reprint Tuberculosis and HIV: a partnership against the most vulnerable
    Pedro Cahn
    Fundacion Huesped, Angel Peluffo 3932 C1202ABB, Buenos Aires, Argentina
    J Int Assoc Physicians AIDS Care (Chic) 2:106-23. 2003
    ..Global distributive injustices in wealth, the burden of disease, and the provision of healthcare are obvious in TB, and clearly show us that the needs of the most vulnerable populations must be met in order to address the problems...
  8. ncbi request reprint Raltegravir: a new antiretroviral class for salvage therapy
    Pedro Cahn
    Department of Clinical Research, Fundacion Huesped, Buenos Aires, Argentina C1202ABB
    Lancet 369:1235-6. 2007
  9. pmc Beyond the first 25 years: The International AIDS Society and its role in the global response to AIDS
    Pedro Cahn
    International AIDS Society, 33, Chemin de l Avanchet, Geneva, Switzerland
    Retrovirology 3:85. 2006
    ..Dr. Pedro Cahn, International AIDS Society (IAS) President and Mr. Craig McClure, IAS Executive Director, provide their thoughts and analysis on the current and future role of the IAS as part of the global response to HIV/AIDS...
  10. ncbi request reprint Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Clin Infect Dis 43:1347-56. 2006
    ....
  11. ncbi request reprint Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy
    Pedro Cahn
    Fundacion Huesped, Angel Peluffo 3932, Buenos Aires, Argentina C1202ABB
    Expert Opin Investig Drugs 13:55-68. 2004
    ..Potency, tolerability, convenient dosing and a low rate of side effects are some of the main characteristics of this new drug...
  12. ncbi request reprint Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials
    Pedro E Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    J Int Assoc Physicians AIDS Care (Chic) 3:92-8. 2004
    ..Atazanavir does not lead to dyslipidemia in ARV-naive patients, and may limit the need for lipid-lowering strategies to reduce the risk of cardiovascular disease...
  13. pmc Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America
    Carina Cesar
    Fundacion Huesped, Buenos Aires, Argentina
    PLoS ONE 5:e10490. 2010
    ..No multi-cohort study has examined rates of and reasons for change of initial HAART in this region...
  14. ncbi request reprint Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Clin Drug Investig 28:129-38. 2008
    ..This study aimed to investigate the multiple-dose pharmacokinetics of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor, in antiretroviral-naive patients with HIV-1 infection...
  15. ncbi request reprint Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Curr Med Res Opin 20:1115-23. 2004
    ....
  16. ncbi request reprint Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen
    Hector Perez
    Fernandes Hospital, Infectious Diseases Unit, Buenos Aires, Argentina
    Antivir Ther 13:135-9. 2008
    ..The aim of this study was to evaluate the emergence of strains resistant to NVP and lamivudine (3TC) after discontinuation of antiretroviral therapy (ART) with 3TC/zidovudine (ZDV)/NVP...
  17. ncbi request reprint Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients
    Pedro Cahn
    Fundacion Huesped, Angel Peluffo 3932, Buenos Aires, Argentina C120 2ABB
    AIDS 20:1261-8. 2006
    ..This study evaluated the antiretroviral efficacy, tolerability and safety of apricitabine monotherapy, administered for 10 days in antiretroviral-naive, HIV-1 infected adults...
  18. ncbi request reprint Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/microL: a randomized trial
    Alejandro J Krolewiecki
    Fundacion Huesped, Arca de Investigaciones Clínicas, Buenos Aires, Argentina
    J Acquir Immune Defic Syndr 41:425-9. 2006
    ..To evaluate clinical, immunologic, and virologic performance of patients with nadir CD4 counts of >350 cells/microL upon treatment interruption...
  19. pmc Determinants of treatment access in a population-based cohort of HIV-positive men and women living in Argentina
    Carlos Zala
    Fundacion Dra Cecilia Grierson, Buenos Aires, Argentina
    Medscape J Med 10:78. 2008
    ..To report emerging data on the use of highly active antiretroviral therapy (HAART) in Argentina by assessing patterns of HAART access and late vs early treatment initiation in a population-based cohort of adults infected with HIV type-1...
  20. doi request reprint Laboratory abnormalities among HIV-1-infected pregnant women receiving antiretrovirals in Latin America and the Caribbean
    Mariana Ceriotto
    Hospital Cecilia Grierson, Buenos Aires, Argentina
    AIDS Patient Care STDS 22:167-71. 2008
  21. ncbi request reprint The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART
    Liliana Belmonte
    Instituto de Investigaciones Hematologicas, Academia Nacional de Medicina, Buenos Aires, Argentina
    AIDS 21:2106-8. 2007
    ..The intestinal mucosa seems to serve as a reservoir poorly influenced by levels of plasma viral load or HAART...
  22. doi request reprint Macrophage HIV-1 infection in duodenal tissue of patients on long term HAART
    Alberto Zalar
    Gastroenterology Unit, Hospital Juan A Fernandez, Buenos Aires, Argentina
    Antiviral Res 87:269-71. 2010
    ..These findings confirm that intestinal macrophages can act as viral reservoirs and permit HIV-1 production even after viral suppression following antiretroviral therapy...
  23. ncbi request reprint Coinfection: Helicobacter pylori/human immunodeficiency virus
    Martin Olmos
    Hospital Fernandez, Buenos Aires, Argentina
    Dig Dis Sci 49:1836-9. 2004
    ..HIV-infected patients with H. pylori had a higher mean CD4 count than HIV-infected individuals without H. pylori. Gastric lesions associated with H. pylori were more severe in the HIV-positive population...
  24. doi request reprint Lack of viral selection in human immunodeficiency virus type 1 mother-to-child transmission with primary infection during late pregnancy and/or breastfeeding
    Ana Ceballos
    National Reference Center for AIDS, Department of Microbiology, University of Buenos Aires School of Medicine, Buenos Aires, Argentina
    J Gen Virol 89:2773-82. 2008
    ..These results could be explained by the less pronounced selective pressure exerted by the immune system in the early stages of the mother's infection, which could play a role in MTCT of HIV-1...
  25. doi request reprint Strengthening accountability in the global response to HIV
    Pedro Cahn
    International AIDS Society, CH 1216 Cointrin, Geneva, Switzerland
    Lancet 372:265. 2008
  26. ncbi request reprint [Endoscopic approach in HIV infected-patients with upper gastrointestinal symptoms]
    Martín Alejandro Olmos
    División de Gastroenterología, Hospital Fernandez, Buenos Aires, Argentina
    Acta Gastroenterol Latinoam 34:120-6. 2004
    ....
  27. pmc HLA-driven convergence of HIV-1 viral subtypes B and F toward the adaptation to immune responses in human populations
    Dario Alberto Dilernia
    Centro Nacional de Referencia para el SIDA, Departamento de Microbiologia, Facultad de Medicina, Universidad de Buenos Aires, Capital Federal, Buenos Aires, Argentina
    PLoS ONE 3:e3429. 2008
    ..Dissecting the dynamics of these escape mutations at a population-level would help to understand how HLA-mediated selection drives the evolution of HIV-1...
  28. pmc G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate
    Laura Rodero
    Departamento Micologia, Instituto Nacional de Enfermedades Infecciosas, ANLIS Dr Carlos G Malbran, Hospital J A Fernandez, Buenos Aires, Argentina
    Antimicrob Agents Chemother 47:3653-6. 2003
    ..Analysis of the 14-alpha lanosterol demethylase gene (ERG11) showed a point mutation in the resistant strain responsible for the amino acid substitution G484S...
  29. ncbi request reprint [HBV and HCV co-infections in HIV positive patients in the "HAART era": new challenges]
    Natalia L Laufer
    Servicio de Infectologia, Hospital Juan A Fernández Buenos Aires
    Medicina (B Aires) 67:82-91. 2007
    ..Nowadays there are new available therapies, diagnostic and follow up techniques for HBV and HCV, what provides a better control of both co-infections...
  30. ncbi request reprint Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth
    Edgardo G Szyld
    Hosp Diego Paroissien, Brazil
    AIDS 20:2345-53. 2006
    ..The a priori hypothesis was that protease inhibitor (PI)-containing regimens are associated with an increased risk of LBW and preterm birth...